ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need.
ProQR's leadership is a strong team with proven track record. Find out who is on our management team, board of directors and scientific advisory board.
Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.
… medicines” The potential of this new technology for RNA therapeutics is immense, says Bart Klein, who was at the … Bart Klein was at the forefront of ProQR's Axiomer® RNAediting technology development. This platform technology …
… oligonucleotides for directing site-specific A-to-I editing by endogenous ADAR enzymes Axiomer® platform … potential in therapeutically relevant models for targeted RNAediting presented at TIDES EU 2018 by Antti Aalto - ProQR …
… USA. ProQR is focused on the development of life changing RNA therapies to meet the unmet need of individuals and … of the communities we serve. Our proprietary Axiomer® RNAediting technology platform enables the editing of …
